Clinical trials: Covid19 Vaccine
SARS-CoV-2 Infection, COVID-19
Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.
For Phase 1 only. Additional information will be provided when Phase 2 is implemented. This is a two-part phase I/II, single-center, observer-blind, randomized, controlled vaccine trial to evaluate the safety, reactogenicity, and…
- Trial name
- NCT05490108
- Testing
- ZR202-CoV, ZR202a-CoV, Comirnaty®
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Healthy
Follow-up Study of Population Vaccinated With COVID-19 Vaccine
A multi-centered clinical follow-up study to investigate the long-term dynamic of COVID-19 antibody level after vaccination.
- Trial name
- NCT04972591
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Qin Ning
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205083
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Rheumatoid Arthritis, Psoriatic Arthritis
Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication
The purpose of this study is to assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive and/or immunomodulating medication for immune-mediated inflammatory…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthritis, Crohn Disease
- Trial name
- Nor-vaC (NCT04798625)
- Where
- 2 sites in Norway
- Volunteers
- 2,300 people
- Sponsor
- Diakonhjemmet Hospital
COVID-19
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a…
- Trial name
- NCT07536308
- Testing
- OCU500
- Where
- 6 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatic Disease
Safety and Immunogenicity of Sars-cov-2 Vaccine in Patients With Rheumatic Diseases
The purpose of this study was to preliminarily evaluate the immunogenicity of sars-cov-2 vaccine in patients with rheumatic diseases.
- Trial name
- NCT05191368
- Testing
- No intervention
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Yunnan University of Chinese Medicine
Chronic Respiratory Failure, Tracheostomy Complication
Parental Perception of COVID-19 Vaccine in Technology Dependent Patients
This study involves conducting a telephonic or in person survey regarding parental perception and attitudes about vaccinating the respective "technology dependent" child with the COVID 19 vaccination.
- Conditions
- Chronic Respiratory Failure, Tracheostomy Complication, Mechanical Ventilation Complication
- Trial name
- NCT05084976
- Testing
- COVID 19 vaccine counseling
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwell Health
Influenza, COVID-19
Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine
This study investigates healthcare workers' attitudes towards co-administering COVID-19 and seasonal influenza vaccines, a method supported globally for its efficiency and potential to lessen healthcare burdens.
- Trial name
- CoVFlu (NCT05781191)
- Testing
- COMIRNATY
- Where
- Italy
- Volunteers
- 8,231 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19 Vaccine
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
This is Phase 1 and 2a, Multi-center, Open-label study designed to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo vaccine in Healthy Adult Volunteers
- Trial name
- NCT05188469
- Testing
- EG-COVID-003, EG-COVID-001, A: EG-COVID
- Where
- Australia
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- EyeGene Inc.
Diabetic Complication, Covid19 Virus Infection
Suspicion of Hypoglycemic Effect of mRNA Based Covid-19 Vaccines (Polyethylene Glycol) Will Happen , Observational Study on Diabetic Patients at Saudia Arabia
vaccines for covid-19 are gold strategy and great achievement at this century for protection against complications of covid-19 , development of many vaccines with different technology represent a big challenge for this disease so…
- Conditions
- Diabetic Complication, Covid19 Virus Infection, Hypoglycemia, Polyethylene Glycol Adverse Reaction
- Trial name
- NCT05087225
- Testing
- polyethelyene glycol
- Where
- Saudi Arabia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia
Covid19, Kidney Diseases
RECOVAC Repeated Vaccination Study
Rationale: The humoral and cellular immune response after two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate…
- Conditions
- Covid19, Kidney Diseases, Vaccine Response Impaired, SARS-CoV2 Infection
- Trial name
- NCT05030974
- Testing
- mRNA-1273, Ad26.COV2.S vaccine
- Where
- 4 sites in Netherlands
- Volunteers
- 336 people
- Sponsor
- University Medical Center Groningen
COVID-19, Vaccine Hesitancy
Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
The purpose of this community-engaged study is to test the ability of county-level strategies to increase uptake of COVID-19 vaccination.
- Trial name
- K-VAC (NCT06505993)
- Testing
- Health Communication, Health Communication + Structural
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Marc Kiviniemi
Safety, Vaccine Reaction
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
A pneumonia of unknown cause detected in Wuhan, China, was first reported in December 2019. On 08 January 2020, the pathogen causing this outbreak was identified as a novel coronavirus 2019.
- Conditions
- Safety, Vaccine Reaction, Vaccine Adverse Reaction, Immunization; Infection
- Trial name
- NCT05171946
- Testing
- S.opt.FL COVID-19 pDNA vaccine
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Iman Almansour
Immunogenicity, Efficacy
New Generation mRNA Booster Vaccine Against Emerging VOCs
Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers…
- Conditions
- Immunogenicity, Efficacy, Safety
- Trial name
- NCT05580159
- Testing
- SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
- Where
- Laos
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hearing, COVID - 19
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
- Conditions
- Hearing, COVID - 19, Ototoxicity
- Trial name
- NCT07254442
- Testing
- Hearing tests
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Zonguldak Bulent Ecevit University
Bullous Dermatoses, Psoriasis
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
This is a randomised controlled trial conducted to prove that the immunological performance of intradermal tozinameran (i.e., Pfizer-BioNTech COVID-19 vaccine) is no worse than the standard intramuscular route in patients with…
- Conditions
- Bullous Dermatoses, Psoriasis, COVID-19 Vaccines
- Trial name
- NCT05406908
- Testing
- tozinameran
- Where
- Thailand
- Volunteers
- 109 people
- Sponsor
- Mahidol University
COVID-19, Pneumococcal Infections
Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years
Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults aged over 60 or 65 years (depending local guidelines) who have never received a pneumococcal vaccine or…
- Trial name
- NVX_PCV20 (NCT05767606)
- Testing
- NVX, PCV20
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695117
- Testing
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)
This study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose.
- Trial name
- NCT05279456
- Testing
- Advax-CpG55.2 adjuvanted recombinant spike protein
- Where
- Australia
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.